INJE PharmacoGenomics Research Center

· Kim WY, Lee SJ, Min JK, Oh KS, Kim DH, Kim HS, Shin JG.

Identification of novel CYP4F2 genetic variants exhibiting decreased catalytic activity in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) (cPMTb)

Prostaglandins Leukot Essent Fatty Acids. 131:6-13 / 2018.04 [LINK]

· Wu S, Jiang F, Wu H, Wang Y, Xu R, Cao J, Lu Q, Zhu X, Zhong Z, Zhao X

Prognostic significance of hypoxia inducible factor-1メ expression in patients with clear cell renal cell carcinoma. (cPMTb)

Mol Med Rep. 17(3):4846-4852 / 2018.03 [LINK]

· Lee S, Yoo HH, In MK, Jin C, Kim DH.

Stereoselectivity in the cytochrome P450-dependent N-demethylation and flavin monooxygenase-dependent N-oxidation of N,N-dimethylamphetamine. (PRCDM)

Arch Pharm Res. 36(11):1385-91 / 2013.11 [LINK]

2013-International

· Kim HS, Chang K, Koh YS, Park MW, Choi YS, Park CS, Oh M, Kim EY, Shon JH, Shin JG, Seung KB.

CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. (BMRC, PRCDM)

Circ Cardiovasc Genet. 6(5):514-21 / 2013.10 [LINK]

2013-International

· Jarrar YB, Cho SA, Oh KS, Kim DH, Shin JG, Lee SJ.

Identification of cytochrome P450s involved in the metabolism of arachidonic acid in human platelets. (BMRC, PRCDM)

Prostaglandins Leukot Essent Fatty Acids. 89(4):227-34 / 2013.09 [LINK]

2013-International

· Park MW, Her SH, Kim HS, Choi YS, Park CS, Koh YS, Park HJ, Kim PJ, Kim CJ, Jeon DS, Shin DI, Seo SM, Yoo KD, Kim DB, Kim HY, Lee JM, Chung WS, Seung KB, Shin JG, Chang K.

Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention. (PRCDM)

Pharmacogenet Genomics. 23(10):558-62 / 2013.10 [LINK]

2013-International

· Lee SJ, Kim WY, Jarrar YB, Kim YW, Lee SS, Shin JG.

Single nucleotide polymorphisms in SULT1A1 and SULT1A2 in a Korean population. (BMRC, PRCDM)

Drug Metab Pharmacokinet. 28(4):372-7 / 2013.05 [LINK]

2013-International

· Lee SJ.

Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. (BMRC, PRCDM)

Front Genet. 3:318 / 2013.02 [LINK]

2013-International

· Kim HJ, Jeong ES, Seo KA, Shin KJ, Choi YJ, Lee SJ, Ghim JL, Sohn DR, Shin JG, Kim DH.

Glucuronidation of a sarpogrelate active metabolite is mediated by UDP-glucuronosyltransferases 1A4, 1A9, and 2B4. (BMRC)

Drug Metab Dispos. 41(8):1529-37 / 2013.08 [LINK]

2013-International

· Kim KP, Kim HS, Sym SJ, Bae KS, Hong YS, Chang HM, Lee JL, Kang YK, Lee JS, Shin JG, Kim TW.

A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. (PRCDM)

Cancer Chemother Pharmacol. 71(6):1609-17 / 2013.06 [LINK]

2013-International

Publications

Product